• +1-646-491-9876
    • +91-20-67278686

    Search

    Mucin 1-Pipeline Review H2 2017

    Mucin 1-Pipeline Review H2 2017

    • Report Code ID: RW0001881471
    • Category Life Sciences
    • No. of Pages 80
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Pipeline Review H2 2017

    Summary

    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) pipeline Target constitutes close to 21 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Mucin 1-Pipeline Review H2 2017 outlays comprehensive information on the Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.

    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Mucin 1 cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene. It acts both as an adhesion and an anti-adhesion protein. It provides a protective layer on epithelial cells against bacterial and enzyme attack. It is involved in cell signaling through phosphorylations and protein-protein interactions. It modulates signaling in ERK SRC and NF-kappa-B pathways. It promotes tumor progression. It regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. The molecules developed by companies in Phase II Phase I Preclinical and Discovery stages are 6 1 6 and 1 respectively. Similarly the universities portfolio in Phase II Preclinical and Discovery stages comprises 1 5 and 1 molecules respectively. Report covers products from therapy areas Oncology and Non Malignant Disorders which include indications Breast Cancer Prostate Cancer Non-Small Cell Lung Cancer Colon Cancer Lung Cancer Ovarian Cancer Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Adenocarcinoma Adenomas Colorectal Cancer Gastric Cancer Metastatic Breast Cancer Metastatic Colorectal Cancer Multiple Myeloma (Kahler Disease) Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Refractory Acute Myeloid Leukemia Relapsed Acute Myeloid Leukemia and Solid Tumor.

    Furthermore this report also reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)
    - The report reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Overview
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Companies Involved in Therapeutics Development
    Akshaya Bio Inc
    Bavarian Nordic A/S
    Boehringer Ingelheim GmbH
    Etubics Corp
    GeoVax Labs Inc
    Merck KGaA
    Minerva Biotechnologies Corp
    Transgene SA
    Vaxil Bio Therapeutics Ltd
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Drug Profiles
    BI-1361849-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target MUC1 for Gastric Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CV-301-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GO-203/NPs-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GO-2032c-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ImMucin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit MUC1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tecemotide-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TG-4010-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine 1 to Target MUC-1 Protein for Breast Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine 2 to Target MUC-1 for Breast Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine 3 to Target MUC-1 Protein for Breast Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target MUC-1 and TLR-2 for Breast Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target MUC-1 for Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target MUC1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target MUC1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target MUC1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target MUC1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target MUC1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target Mucin 1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Dormant Products
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Discontinued Products
    Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)-Product Development Milestones
    Featured News & Press Releases
    May 23 2017 Vaxil Launches Manufacturing of ImMucin Immunotherapy for Upcoming Clinical Trials
    Mar 21 2017 Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer
    Mar 13 2017 First Patient Dosed in Phase 2 Trial Evaluating Transgenes TG4010 in Combination With Opdivo (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer
    Mar 10 2017 Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer
    Mar 03 2017 Vaxil Announces Novel Immunotherapy Poster Presentation at 2017 American Association for Cancer Research Meeting
    Jan 04 2017 Bristol-Myers Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer
    Dec 29 2016 Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer
    Dec 07 2016 UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Nov 29 2016 Vaxil Reports Preliminary Data From Checkpoint Inhibitors in Combination With Immucin
    Aug 15 2016 Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study
    Aug 04 2016 Vaxil Announces Key US Patent and Trademark Office Notice of Allowance for Its Immunotherapy
    Jun 16 2016 Vaxil Receives Positive Response From European Patent Office for the Allowance of the Immunotherapy Orphan Drug Designated ImMucin
    Apr 20 2016 Studies published in "Oncogene" demonstrate that MUC1-C regulates DNA methylation in human carcinoma cells
    Mar 31 2016 Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform Including Its ImMucin Cancer Vaccine
    Mar 16 2016 Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indication H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Akshaya Bio Inc H2 2017
    Pipeline by Bavarian Nordic A/S H2 2017
    Pipeline by Boehringer Ingelheim GmbH H2 2017
    Pipeline by Etubics Corp H2 2017
    Pipeline by GeoVax Labs Inc H2 2017
    Pipeline by Merck KGaA H2 2017
    Pipeline by Minerva Biotechnologies Corp H2 2017
    Pipeline by Transgene SA H2 2017
    Pipeline by Vaxil Bio Therapeutics Ltd H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Akshaya Bio Inc
    Bavarian Nordic A/S
    Boehringer Ingelheim GmbH
    Etubics Corp
    GeoVax Labs Inc
    Merck KGaA
    Minerva Biotechnologies Corp
    Transgene SA
    Vaxil Bio Therapeutics Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//mucin-1-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//mucin-1-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//mucin-1-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments